TERF2IP and breast cancer: Accordingly, the overexpression of RAP1 has been reported in breast cancer [25], gastric carcinoma [26], non-small cell lung cancer [27], mantle cell lymphoma [28], multiple melanoma [29], colorectal cancer [30], and renal cell carcinoma [31].